Feprazone

Synonyms: DA2370; Prenazone; Zepelin
Feprazone (DA2370; Prenazone) 是保泰松 Phenylbutazone (MS-T49855) 的类似物,作为一种非甾体抗炎剂,具有镇痛和退热活性,通过抑制环加氧酶 COX-2 的活性发挥作用,并能通过减少线粒体活性氧 (ROS) 的产生来缓解游离脂肪酸 (FFA) 诱导的氧化应激,同时降低 MMP-2 和 MMP-9 的表达,此外还能在分化的 3T3-L1 细胞中抑制脂肪形成并增加脂肪分解,可用于动脉粥样硬化和抗肥胖的研究。
产品编号: MS-Q32831 纯度: 99.88% CAS No.: 30748-29-9 分子式: C20H20N2O2 分子量: 320.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Feprazone (DA2370; Prenazone) 是保泰松 Phenylbutazone (MS-T49855) 的类似物,作为一种非甾体抗炎剂,具有镇痛和退热活性,通过抑制环加氧酶 COX-2 的活性发挥作用,并能通过减少线粒体活性氧 (ROS) 的产生来缓解游离脂肪酸 (FFA) 诱导的氧化应激,同时降低 MMP-2 和 MMP-9 的表达,此外还能在分化的 3T3-L1 细胞中抑制脂肪形成并增加脂肪分解,可用于动脉粥样硬化和抗肥胖的研究。

生物实验数据

生物活性 Feprazone (DA2370; Prenazone), an analog of Phenylbutazone (MS-T49855), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities that acts by inhibiting the activity of cyclooxygenase COX-2, alleviates free fatty acid (FFA)-induced oxidative stress by reducing mitochondrial reactive oxygen species (ROS) production, decreases MMP-2 and MMP-9 expression, and additionally inhibits adipogenesis and increases lipolysis in differentiated 3T3-L1 cells, making it useful for research on atherosclerosis and anti-obesity.
IC50 & Target

COX, Reactive oxygen species, MMP

体外研究
(In Vitro)

Feprazone (2.5-10 μM; 48 h) rescues cell viability of FFAs-stimulated human aortic endothelial cells (HAECs).
Feprazone (5, 10 μM; 24 h) reduces ROS production in HAECs to only 2.4- and 1.6-fold at 5 and 10 μM, respectively, while 300 μM FFA increases ROS production by 3.4-fold; also decreases the mRNA expression and secretion of cytokines CCL5, IL-6, and IL-8, as well as MMP-2 and MMP-9.
Feprazone (5, 10 μM; 6 h) decreases TLR4 and MyD88 activities, as well as reduces the phosphorylation of p65 and subsequent activation of NF-κB.
Feprazone (30 and 60 μM; 7 days) suppresses the adipogenesis in differentiating 3 T3-L1 cells; reduced the triglyceride content and increased lipolysis during 3 T3-L1 adipogenesis.

Cell Viability Assay

Cell Line: HAECs (stimulated with 300 μM FFAs)
Concentration: 2.5, 5 and 10 μM
Incubation Time: 48 h
Result: Rescued cell viability to 81 and 93% of baseline at 5 and 10 μM, while FFAs reduced the cell viability to 63% of baseline.

RT-PCR

Cell Line: HAECs (stimulated with 300 μM FFAs)
Concentration: 5 and 10 μM
Incubation Time: 24 h
Result: Decreased the mRNA expression and secretion of cytokines CCL5, IL-6, and IL-8 in a dose-dependent manner.
Dose-dependently mitigated the VCAM-1 and ICAM-1 expression to only 1.7- and 1.8-fold, respectively, while FFA increased to 2.8- and 3.4-fold, respectively.

Western Blot Analysis

Cell Line: HAECs (stimulated with 300 μM FFAs)
Concentration: 5 and 10 μM
Incubation Time: 6 h
Result: Decreased TLR4 and MyD88 expression, as well as reduced the phosphorylation of p65 and subsequent activation of NF-κB.
体内研究
(In Vivo)

Significantly inhibited the adipocyte size, the visceral adipocyte tissue weights and the average bodyweights in HFD mice.

Animal Model: Male C57BL/6 N mice [high-fat diet (HFD) induced obesity model]
Dosage: 75 mg/kg
Administration: (no described in the research)
Result: The visceral adipocyte tissue weights of mice in the control, HFD, and HFD + Feprazone groups were 0.38, 3.51, and 2.37 g, respectively.
The average bodyweights of mice in the control, HFD, and HFD + Feprazone groups were 29.6, 41.3, and 34.1 g, respectively.
性状 固体
颜色 White to off-white

化学信息

分子量 320.39
分子式 C20H20N2O2
CAS No. 30748-29-9
别名 DA2370; Prenazone; Zepelin

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 12.5 mg/mL (39.01 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.1212 mL15.6060 mL31.2120 mL78.0299 mL
5 mM0.6242 mL3.1212 mL6.2424 mL15.6060 mL
10 mM0.3121 mL1.5606 mL3.1212 mL7.8030 mL
15 mM0.2081 mL1.0404 mL2.0808 mL5.2020 mL
20 mM0.1561 mL0.7803 mL1.5606 mL3.9015 mL
25 mM0.1248 mL0.6242 mL1.2485 mL3.1212 mL
30 mM0.1040 mL0.5202 mL1.0404 mL2.6010 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础